Natalizumab - Biologic Drug Details

Summary for natalizumab

Tradenames:	1
High Confidence Patents:	6
Applicants:	2
BLAs:	2
Suppliers: see list	2
Recent Clinical Trials:	See clinical trials for natalizumab

Recent Clinical Trials for natalizumab

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
King's College London	NA
Rosetrees Trust	NA
Washington University School of Medicine	Phase 1

See all natalizumab clinical trials

Pharmacology for natalizumab

Mechanism of Action	Integrin Receptor Antagonists
Established Pharmacologic Class	Integrin Receptor Antagonist

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for natalizumab Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for natalizumab Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Biogen Inc.	TYSABRI	natalizumab	Injection	125104		2037-02-13	DrugPatentWatch analysis and company disclosures
Biogen Inc.	TYSABRI	natalizumab	Injection	125104		2034-09-23	DrugPatentWatch analysis and company disclosures
Biogen Inc.	TYSABRI	natalizumab	Injection	125104		2033-12-06	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for natalizumab Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Biogen Inc.	TYSABRI	natalizumab	Injection	125104		2034-01-08	Patent claims search
Biogen Inc.	TYSABRI	natalizumab	Injection	125104		2036-08-10	Patent claims search
Biogen Inc.	TYSABRI	natalizumab	Injection	125104		2034-05-27	Patent claims search

International Patents for natalizumab

Country	Patent Number	Estimated Expiration
Argentina	043144
Portugal	3212230
Japan	6985349

Supplementary Protection Certificates for natalizumab

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2021032	Norway		PRODUCT NAME: VERISIGUAT OG DENS SALTER SOLVATER OG SOLVATER AV SALTER; REG. NO/DATE: EU/1/21/1561 20210805
132006901441326	Italy		AUTHORISATION NUMBER(S) AND DATE(S): EU/1/06/346/001, 20060627
2022009	Norway		PRODUCT NAME: LUMASIRAN, OPTIONALLY IN THE FORM OF A SALT; REG. NO/DATE: EU/1/20/1496 20201124

Natalizumab: Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

Natalizumab is a humanized monoclonal antibody targeting the alpha-4 integrin subunit of very late antigen-4 (VLA-4) on leukocytes. Its therapeutic application is primarily in the treatment of relapsing forms of multiple sclerosis (MS) and Crohn’s disease. The drug's market performance is influenced by patent exclusivity, competition from biosimil entrants, and evolving treatment landscapes for its target indications.

What is Natalizumab's Current Market Position?

As of the latest available data, natalizumab, primarily marketed as Tysabri by Biogen, holds a significant position in the advanced treatment of relapsing forms of MS. Its efficacy in reducing relapse rates and new T2 lesion formation in MRI scans has established it as a valuable therapeutic option for patients with active disease.

• Key Indications:

  • Relapsing forms of Multiple Sclerosis (MS)
  • Crohn's Disease (moderately to severely active)

• Market Share Drivers:

  • Demonstrated efficacy in clinical trials.
  • Established safety profile with long-term use.
  • Physician familiarity and prescribing habits.

• Competitive Landscape: Natalizumab faces competition from other disease-modifying therapies (DMTs) for MS, including injectable interferons and glatiramer acetate, as well as newer oral and infused agents with different mechanisms of action. For Crohn's disease, it competes with biologics such as infliximab, adalimumab, and ustekinumab. The advent of biosimil versions of natalizumab will further intensify this competition and impact pricing.

What are the Key Patent Expirations and Biosimilar Market Entry Timelines?

The patent landscape for natalizumab has been a critical determinant of its market exclusivity and subsequent revenue generation. The primary patent protection for Tysabri has largely expired in major markets, opening the door for biosimilar development and market entry.

• US Patent Expiration: The key composition of matter patents for natalizumab expired in the United States. Specific patent numbers and their expiration dates are subject to complex legal challenges and extensions, but core protections have lapsed.

  • Key patents have expired, allowing for biosimilar development.

• European Patent Expiration: Similar to the US, European patent protections for natalizumab have also expired.

  • Market entry for biosimil products in Europe is ongoing or imminent.

• Biosimilar Approvals and Launches: Regulatory bodies globally have been reviewing and approving natalizumab biosimil applications. The timing and success of these launches vary by region.

  • Samsung Bioepis (Italy): Launched its biosimilar in some European markets.
  • Novartis (Sandoz): Has developed and sought approval for its biosimilar.
  • Amneal Pharmaceuticals: Also developing a biosimilar.
  • Others: Multiple pharmaceutical companies are in various stages of biosimilar development and commercialization.

• Impact of Biosimil Entry: The introduction of biosimil natalizumab is expected to lead to significant price erosion, increased market accessibility, and shifts in market share from the originator product.

  • Price Reduction: Estimates suggest biosimilar entry can lead to price decreases of 20-40% or more.
  • Market Share Erosion: The originator product is projected to experience a gradual decline in market share as biosimil alternatives gain traction.

What is Natalizumab's Historical and Projected Financial Performance?

Natalizumab has been a substantial revenue generator for Biogen. Its financial trajectory is now entering a new phase characterized by declining originator sales due to biosimilar competition and the continued demand for effective MS and Crohn's treatments.

• Biogen's Revenue from Tysabri (USD Billions):

  • 2020: $2.03
  • 2021: $1.97
  • 2022: $1.95
  • 2023 (estimated/partial year data): Forecasts indicate a continued downward trend.

• Projected Market Size for Natalizumab and Biosimil Equivalents: While originator sales are expected to decline, the overall market for natalizumab and its biosimil counterparts is projected to remain substantial due to the chronic nature of MS and Crohn's disease and the demonstrated clinical value.

  • The global natalizumab market (including biosimil equivalents) is estimated to be worth several billion dollars annually and is expected to continue to attract significant commercial interest.
  • Growth Drivers for Biosimil Market: Increasing healthcare expenditure, demand for cost-effective treatments, and favorable regulatory pathways for biosimilar adoption.

• Factors Influencing Future Financials:

  • Pricing Pressure: Intensified by multiple biosimilar competitors.
  • Market Penetration of Biosimil: Dependent on physician and payer acceptance.
  • Pipeline Competition: Emergence of novel therapies for MS and Crohn's that may offer improved efficacy or convenience.
  • Geographic Market Dynamics: Different adoption rates and regulatory approvals across regions.

What are the Primary R&D and Commercial Challenges?

The development and commercialization of natalizumab, and now its biosimilar counterparts, present specific R&D and commercial hurdles.

• R&D Challenges:

  • Manufacturing Complexity: Monoclonal antibodies require sophisticated and costly manufacturing processes. Ensuring consistent quality and yield for biosimil production is critical.
  • Clinical Equivalence Demonstration: Biosimilar developers must conduct rigorous comparative studies to demonstrate analytical, clinical, and immunogenicity equivalence to the reference product. This is time-consuming and expensive.
  • Immunogenicity: Natalizumab carries a risk of progressive multifocal leukoencephalopathy (PML), a rare but serious opportunistic infection, which can be exacerbated by immunogenicity. Monitoring and managing this risk is paramount for both originator and biosimil products.

• Commercial Challenges:

  • Market Access and Reimbursement: Securing favorable formulary placement and reimbursement from payers is crucial, especially given the competitive landscape and potential for price negotiations.
  • Physician and Patient Education: Educating healthcare providers and patients about the safety, efficacy, and interchangeability (where applicable) of biosimil natalizumab is essential for uptake.
  • Branding and Trust: The originator product has established brand recognition. Biosimilar manufacturers must build trust and a strong reputation in the market.
  • PML Risk Management: The stringent risk evaluation and mitigation strategies (REMS) for natalizumab, designed to minimize the risk of PML, must be adhered to by all manufacturers. This includes patient and physician education and specialized monitoring programs.

What is the Future Outlook for Natalizumab and its Biosimil Market?

The future outlook for natalizumab and its biosimilar market is characterized by a bifurcated trajectory: a decline in originator sales offset by the growth of the biosimilar segment.

• Originator Product (Tysabri):

  • Expected to experience a steady decline in revenue due to biosimilar competition.
  • May retain a portion of the market share based on established physician preference and specific patient profiles.

• Biosimilar Natalizumab:

  • Poised for significant growth as biosimilar products gain regulatory approvals and market penetration.
  • Will likely drive down overall treatment costs for natalizumab.
  • Competition among multiple biosimilar manufacturers will lead to further pricing pressures.

• Market Dynamics:

  • Increased Accessibility: Biosimil availability is anticipated to broaden patient access to this class of therapy.
  • Healthcare System Savings: Biosimil adoption is a key strategy for healthcare systems to manage drug expenditures.
  • Therapeutic Evolution: The long-term market position will also depend on the development of next-generation therapies for MS and Crohn's disease that may offer differentiated benefits or improved safety profiles.

Key Takeaways

• Natalizumab, a biologic for MS and Crohn's, faces significant market shifts due to patent expirations.
• Biosimilar versions are entering the market across major regions, driving price competition.
• Biogen's Tysabri revenue has stabilized but is projected to decline with increased biosimilar penetration.
• The overall market for natalizumab and its biosimil equivalents is expected to remain substantial, driven by the chronic nature of its target diseases.
• Manufacturing complexity, regulatory hurdles, and robust risk management strategies (especially for PML) are key challenges for both originator and biosimilar developers.
• The future will see declining originator sales and growing biosimilar market share, influencing cost-effectiveness and patient access.

Frequently Asked Questions

What is the primary mechanism of action for natalizumab?

Natalizumab inhibits the migration of leukocytes from the bloodstream into the central nervous system by blocking the alpha-4 integrin subunit on circulating lymphocytes. This prevents these cells from binding to vascular cell adhesion molecule-1 (VCAM-1) and other adhesion molecules on the endothelium of blood vessels.

What are the main risks associated with natalizumab treatment?

The most serious risk associated with natalizumab is progressive multifocal leukoencephalopathy (PML), a rare but potentially fatal demyelinating disease of the central nervous system. Other risks include infusion reactions, hypersensitivity reactions, and an increased risk of certain infections.

How does a biosimilar differ from a generic drug?

Biosimil and generic drugs are both versions of an original drug that have lost patent protection. However, because biologics are complex molecules produced by living organisms, biosimil manufacturers cannot produce exact copies. Instead, they demonstrate that their product is highly similar to the reference biologic in terms of structure, function, and efficacy, with no clinically meaningful differences in safety or purity. Generic drugs, by contrast, are exact copies of small-molecule drugs.

What is the recommended monitoring for patients on natalizumab?

Patients on natalizumab require regular monitoring for signs and symptoms of PML and other infections. This typically includes periodic neurological examinations, MRI scans, and monitoring of immune status. Specific risk management programs, such as the TOUCH Prescribing Program in the US, outline detailed monitoring requirements.

Will biosimilar natalizumab be directly interchangeable with Tysabri?

Interchangeability, the ability for a biosimilar to be substituted for the reference product by a pharmacist without the intervention of the prescribing healthcare provider, is determined by regulatory agencies on a case-by-case basis. While some biosimil natalizumab products have been approved, their interchangeability status varies by region and regulatory jurisdiction, and it is not universally granted.